Search research articles
Contact Us
Filters
Showing results (11-20 of 126) with videos related to
Page
of 13
Sort By:
Lancet (London, England)
|
September 14, 2010
How many lives does an ulcerative colitis patient have?
Daniel C Baumgart
Current Opinion in Investigational Drugs (London, England : 2000)
|
April 27, 2010
CB-01-05-MMX, a novel oral controlled-release low molecular weight heparin for the potential treatment of ulcerative colitis
Daniel C Baumgart
NPJ Digital Medicine
|
September 14, 2020
Digital advantage in the COVID-19 response: perspective from Canada's largest integrated digitalized healthcare system
Daniel C Baumgart
Lancet (London, England)
|
November 6, 2007
Virchow's node
Daniel C Baumgart, Andreas Fischer
Drug Design, Development and Therapy
|
January 2, 2015
Designing biologic selectivity for inflammatory bowel disease--role of vedolizumab
Niklas Krupka, Daniel C Baumgart
American Family Physician
|
July 31, 2003
Photo quiz. Obesity and daytime sleepiness. Prader-Willi syndrome
Daniel C Baumgart, Helga Gerl
Inflammopharmacology
|
December 30, 2011
Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis
Saskia Thomas, Daniel C Baumgart
The New England Journal of Medicine
|
September 29, 2021
Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease
Daniel C Baumgart, Catherine Le Berre
Recent Patents on Anti-Infective Drug Discovery
|
January 8, 2011
Viral gastroenteritis in adults
Alexander J Eckardt, Daniel C Baumgart
Lancet (London, England)
|
August 24, 2012
Crohn's disease
Daniel C Baumgart, William J Sandborn
Page
of 13
Search research articles
Search
Showing results (11-20 of 126) with videos related to
Sort By:
Page
of 13
Lancet (London, England)
|
September 14, 2010
How many lives does an ulcerative colitis patient have?
Daniel C Baumgart
Current Opinion in Investigational Drugs (London, England : 2000)
|
April 27, 2010
CB-01-05-MMX, a novel oral controlled-release low molecular weight heparin for the potential treatment of ulcerative colitis
Daniel C Baumgart
NPJ Digital Medicine
|
September 14, 2020
Digital advantage in the COVID-19 response: perspective from Canada's largest integrated digitalized healthcare system
Daniel C Baumgart
Lancet (London, England)
|
November 6, 2007
Virchow's node
Daniel C Baumgart, Andreas Fischer
Drug Design, Development and Therapy
|
January 2, 2015
Designing biologic selectivity for inflammatory bowel disease--role of vedolizumab
Niklas Krupka, Daniel C Baumgart
American Family Physician
|
July 31, 2003
Photo quiz. Obesity and daytime sleepiness. Prader-Willi syndrome
Daniel C Baumgart, Helga Gerl
Inflammopharmacology
|
December 30, 2011
Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis
Saskia Thomas, Daniel C Baumgart
The New England Journal of Medicine
|
September 29, 2021
Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease
Daniel C Baumgart, Catherine Le Berre
Recent Patents on Anti-Infective Drug Discovery
|
January 8, 2011
Viral gastroenteritis in adults
Alexander J Eckardt, Daniel C Baumgart
Lancet (London, England)
|
August 24, 2012
Crohn's disease
Daniel C Baumgart, William J Sandborn
Page
of 13